ClinicalTrials.Veeva

Menu

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Roche logo

Roche

Status and phase

Completed
Phase 3

Conditions

Chronic Hepatitis B

Treatments

Drug: PEGASYS

Study type

Interventional

Funder types

Industry

Identifiers

NCT00048945
WV16240

Details and patient eligibility

About

The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.

Enrollment

820 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical diagnosis of hepatitis B
  • Not pregnant

Exclusion criteria

  • Treatment for hepatitis B in past 6 months
  • Other hepatitis infections
  • Severe liver disease
  • Pregnancy

Trial contacts and locations

74

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems